

Table S1. Residual Lifetime Incidence, Current Prevalence, and Unconditional Lifetime Incidence in Adults Aged 30 or Older, by Race
a. African-Americans

Stage	Current Age 30–49			Current Age 50–64			Current Age 65+		
	Residual Lifetime Incidence % (95% CI)	Current Prevalence % (95% CI)	Unconditional Lifetime Incidence % (95% CI)	Residual Lifetime Incidence % (95% CI)	Current Prevalence % (95% CI)	Unconditional Lifetime Incidence % (95% CI)	Residual Lifetime Incidence % (95% CI)	Current Prevalence % (95% CI)	Unconditional Lifetime Incidence % (95% CI)
CKD	43.83 (42.04-45.58)	5.60 (4.53-6.67)	46.98 (45.90-48.04)	42.11 (39.55-44.39)	13.62 (11.90-15.34)	49.99 (48.83-51.01)	33.87 (28.79-38.65)	39.80 (36.61-42.99)	60.19 (59.40-61.12)
CKD Stage 3a+	36.14 (34.96-37.58)	1.16 (0.71-1.60)	36.88 (36.00-38.03)	34.74 (32.69-36.81)	6.38 (4.95-7.80)	38.90 (37.94-39.94)	28.55 (24.44-32.36)	29.81 (27.02-32.61)	49.85 (49.08-50.64)
CKD Stage 3b+	22.55 (21.65-23.52)	0.60 (0.28-0.91)	23.01 (22.36-23.73)	23.77 (22.09-25.46)	2.76 (1.82-3.71)	25.88 (24.98-26.81)	24.76 (22.18-27.26)	10.64 (8.68-12.60)	32.77 (31.99-33.58)
CKD Stage 4+	12.35 (11.57-13.27)	0.38 (0.11-0.64)	12.68 (12.14-13.37)	13.85 (12.19-15.30)	1.70 (0.99-2.40)	15.31 (14.30-16.14)	14.35 (12.49-15.97)	3.31 (2.11-4.51)	17.19 (16.44-17.74)
CKD Stage 5	6.56 (5.99-7.13)	—	6.56 (5.99-7.13)	8.45 (7.73-9.13)	—	8.45 (7.73-9.13)	7.22 (6.52-7.80)	—	7.22 (6.52-7.80)

b. Non-African-Americans

Stage	Current Age 30–49			Current Age 50–64			Current Age 65+		
	Residual Lifetime Incidence % (95% CI)	Current Prevalence % (95% CI)	Unconditional Lifetime Incidence % (95% CI)	Residual Lifetime Incidence % (95% CI)	Current Prevalence % (95% CI)	Unconditional Lifetime Incidence % (95% CI)	Residual Lifetime Incidence % (95% CI)	Current Prevalence % (95% CI)	Unconditional Lifetime Incidence % (95% CI)
CKD	55.49 (54.77-56.25)	3.80 (3.35-4.25)	57.18 (56.69-57.72)	53.24 (51.90-54.46)	9.42 (8.48-10.36)	57.65 (56.89-58.32)	42.46 (40.41-44.51)	39.64 (38.32-40.95)	65.27 (64.81-65.77)
CKD Stage 3a+	48.56 (47.98-49.18)	0.65 (0.44-0.85)	48.89 (48.42-49.40)	45.87 (44.79-46.85)	4.65 (3.93-5.37)	48.39 (47.76-48.94)	38.15 (35.40-40.81)	30.08 (27.71-32.45)	56.75 (56.36-57.21)
CKD Stage 3b+	24.48 (24.00-24.95)	0.13 (0.03-0.23)	24.58 (24.18-24.98)	23.78 (23.06-24.45)	0.75 (0.52-0.97)	24.35 (23.80-24.85)	19.29 (17.75-20.74)	10.61 (9.44-11.79)	27.85 (27.44-28.22)
CKD Stage 4+	9.06 (8.73-9.49)	0.08 (0.02-0.14)	9.13 (8.86-9.50)	8.57 (8.08-9.16)	0.17 (0.07-0.27)	8.72 (8.33-9.22)	7.52 (6.74-8.29)	2.52 (2.08-2.97)	9.85 (9.51-10.20)
CKD Stage 5	2.73 (2.52-2.96)	—	2.73 (2.52-2.96)	2.72 (2.46-2.96)	—	2.72 (2.46-2.96)	2.22 (2.04-2.39)	—	2.22 (2.04-2.39)

Notes: Residual lifetime incidence for CKD shows the projected percentage of persons who do not currently have CKD and who will develop CKD in their lifetime. Residual lifetime incidence for CKD stage 3a+ shows the projected percentage of persons with current eGFR ≥ 60 ml/min/1.73 m² who will develop eGFR < 60 ml/min/1.73 m² in their lifetime. Residual lifetime incidence for CKD stage 3b+, stage 4+, and stage 5 are defined in a similar manner, with eGFR cut points of 45, 30, and 15 ml/min/1.73 m², respectively. Current prevalence estimates come from NHANES data from 1999–2010; NHANES does not have enough observations to support separate estimates for stage 5. Unconditional lifetime incidence of CKD accounts for persons who currently have CKD (based on NHANES) and persons currently alive who will develop CKD in their lifetime (as projected by the model). CI = confidence interval; CKD = chronic kidney disease; NHANES = National Health and Nutrition Examination Survey.